The objective of the present work was to estimate the clinical, prophylactic, and microbiological effectiveness of
fusafungine applied for the treatment of acute
rhinosinusitis (ARS) in the children that develops as a consequence of acute stenosing laryngotracheitis. The study included 61 children presenting with ARS and concomitant acute stenosing laryngotracheitis (ASLT) that were treated with
fusafungine (Bioparox). Both tolerance and safety of this preparation were evaluated. Fusaferine was prescribed after reduction of pharyngeal
stenosis. The children were divided into two groups. Group 1 was comprised of the patients with the respiratory symptoms and
rhinosinusitis (n = 36), group 2 consisted of the children with the respiratory symptoms in the absence of
rhinosinusitis (n = 25). Subgroups of the children treated with
fusafungine and without it were distinguished to estimate the clinical, prophylactic, and microbiological effectiveness of fusafungide. Within the first days after hospitalization, 59% of the children with diagnosis ASLT developed bilateral
rhinosinusitis, in all probability of viral etiology.
Fusafungine produced the clinically apparent effect in the patients with ASLT regardless of the presence of ARS. Specifically, this preparation decreased the degree of
hypertrophy of pharyngeal tonsils three times faster than standard
therapy; moreover, it reduced the requirement for systemic
antibiotics by 1.9 times. The treatment with fusaferine prevented the development of acute bilateral
rhinosinusitis in the children with ASLT and promoted compete decontamination of the nasopharynx from M. catarrhalis, Str.
pneumonia, Str. pyogenes, H.
influenza, Cor. s the nasopharynx pecies, E. faecalis, and C. albicans. The frequency of adverse reactions of organoleptic character was estimated at 16.6%.